Nina Grytten1, Kjell-Morten Myhr2, Elisabeth G Celius3, Espen Benjaminsen4, Margitta Kampman5, Rune Midgard6, Anita Vatne7, Jan H Aarseth8, Trond Riise9, Øivind Torkildsen10. 1. Norwegian Multiple Sclerosis Competence Centre, Department of Neurology, Haukeland University Hospital, Bergen, Norway. 2. Department of Clinical Medicine, University of Bergen, Bergen, Norway/Department of Neurology, Haukeland University Hospital, Bergen, Norway. 3. Department of Neurology, Oslo University Hospital, Ullevål, Oslo, Norway/Institute of Clinical Medicine, University of Oslo, Oslo, Norway. 4. Department of Neurology, Nordland Hospital, Bodø, Norway. 5. Department of Neurology, University Hospital of North Norway, Tromsø, Norway. 6. Department of Neurology, Molde Hospital, Molde, Norway/Norwegian University of Science and Technology, Trondheim, Norway. 7. Department of Rehabilitation, Hospital of Southern Norway, Kristiansand, Norway. 8. Norwegian MS Registry and Biobank, Haukeland University Hospital, Bergen, Norway. 9. Norwegian Multiple Sclerosis Competence Centre, Department of Neurology, Haukeland University Hospital, Bergen, Norway/Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway. 10. Norwegian Multiple Sclerosis Competence Centre, Department of Neurology, Haukeland University Hospital, Bergen, Norway/Department of Clinical Medicine, University of Bergen, Bergen, Norway/Department of Neurology, Haukeland University Hospital, Bergen, Norway.
Abstract
BACKGROUND: Risk of cancer in multiple sclerosis (MS) patients compared to their siblings is unknown. OBJECTIVE: The objective was to prospectively investigate the risk of cancer among MS patients compared to siblings without MS and to population controls. METHODS: We retrieved data on MS patients born between 1930 and 1979 from the Norwegian Multiple Sclerosis Registry and population studies and on cancer diagnosis from the Cancer Registry of Norway. We used adjusted Cox proportional hazard regression to estimate cancer risk among 6883 MS patients, 8918 siblings without MS, and 37,919 population controls. RESULTS: During 65 years of follow-up, cancer risk among MS patients was higher than that among population controls (hazard ratio (HR) = 1.14, 95% confidence interval (CI): 1.05-1.23) in respiratory organs (HR = 1.66, 95% CI: 1.26-2.19), urinary organs (HR = 1.51, 95% CI: 1.12-2.04), and the central nervous system (HR = 1.52, 95% CI: 1.11-2. 09). Siblings had higher risk of hematological cancers compared with MS patients (HR = 1.82, 95% CI: 1.21-2.73) and population controls (HR = 1.72, 95% CI: 1.36-2.18). CONCLUSION: MS patients were associated with increased risk of cancer compared to population controls. Siblings had increased risk of hematological cancer. This indicates that MS and hematological cancer could share a common etiology.
BACKGROUND: Risk of cancer in multiple sclerosis (MS) patients compared to their siblings is unknown. OBJECTIVE: The objective was to prospectively investigate the risk of cancer among MSpatients compared to siblings without MS and to population controls. METHODS: We retrieved data on MSpatients born between 1930 and 1979 from the Norwegian Multiple Sclerosis Registry and population studies and on cancer diagnosis from the Cancer Registry of Norway. We used adjusted Cox proportional hazard regression to estimate cancer risk among 6883 MSpatients, 8918 siblings without MS, and 37,919 population controls. RESULTS: During 65 years of follow-up, cancer risk among MSpatients was higher than that among population controls (hazard ratio (HR) = 1.14, 95% confidence interval (CI): 1.05-1.23) in respiratory organs (HR = 1.66, 95% CI: 1.26-2.19), urinary organs (HR = 1.51, 95% CI: 1.12-2.04), and the central nervous system (HR = 1.52, 95% CI: 1.11-2. 09). Siblings had higher risk of hematological cancers compared with MSpatients (HR = 1.82, 95% CI: 1.21-2.73) and population controls (HR = 1.72, 95% CI: 1.36-2.18). CONCLUSION:MSpatients were associated with increased risk of cancer compared to population controls. Siblings had increased risk of hematological cancer. This indicates that MS and hematological cancer could share a common etiology.
Authors: Dimitrios Papadopoulos; Panagiotis Gklinos; Giorgos Psarros; Konstantina Drellia; Eumorphia Maria Delicha; Tim Friede; Dimos D Mitsikostas; Richard S Nicholas Journal: J Neurol Date: 2022-01-23 Impact factor: 4.849
Authors: Mette Nørgaard; Katalin Veres; Finn T Sellebjerg; Lise S Svingel; Caroline Foch; Emmanuelle Boutmy; Meritxell Sabidó; Melinda Magyari Journal: Mult Scler J Exp Transl Clin Date: 2021-11-23